1Orgogozo JM,Rigaud AS,Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial. Stroke, 2002,33 (7) : 1834-1839.
2Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist, 2007, 13(1) :37-41.
4Tariot PN. Contemporary issues in the treatment of Alzheim- ers' disease: angible benefits of current therapies[J]. J Clin Psychiatry, 2006, 67(Suppl 3): 15-22.
5Erkinjuntti T, Roman G, Ganthier S, et al. Emerging thera- pies for vascular dementia and vascular cognitive impair- ment[J]. Stroke, 2004, 35(4): 1010-1017.
6Nagata K, Sato M, Satoh Y, et al. Hemodynamic aspects of Alzheimer's disease[J]. Ann NY Acad Sci, 2002, 977: 391- 402.
7Kumar S. Memantine: pharmacological properties and clini- cal uses[J]. Neurol India, 2004, 52(3): 307-309.
8Berthier ML, Green C, Lars JP, et al. Memantine and con- straint-induced aphasia therapy in chronic poststroke apha- sia[J]. Ann Neurol, 2009, 65(7): 577-585.
9Emre M, Mecocci P, Stender K. Pooled analyses on cogni- tive effects of memantine in patients with moderate to se- vere Alzheimer's disease[J]. J Alzheimers Dis, 2008, 14(2): 193-199.
